Dyne Therapeutics (DYN) Projected to Post Earnings on Monday

Key Points

• Dyne Therapeutics is slated to release its Q2 2025 earnings on August 11, expecting earnings of ($0.99) per share, following a previous announcement of ($0.97) EPS that beat estimates.
• The company's stock has seen a 2.1% increase in price, reaching $10.26, with a market capitalization of $1.46 billion.
• CEO John Cox significantly increased his stake in the company by purchasing 100,000 shares at an average price of $9.11 per share, raising his ownership to over $2.2 million.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Dyne Therapeutics to post earnings of ($0.99) per share for the quarter.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Dyne Therapeutics Stock Up 2.1%

Dyne Therapeutics stock traded up $0.21 during midday trading on Monday, reaching $10.26. The stock had a trading volume of 127,653 shares, compared to its average volume of 2,557,121. The firm's fifty day simple moving average is $10.71 and its 200-day simple moving average is $11.43. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $47.45. The stock has a market capitalization of $1.46 billion, a P/E ratio of -2.66 and a beta of 1.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DYN. Royal Bank Of Canada dropped their target price on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 29th. Chardan Capital lowered their price target on Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. Jones Trading initiated coverage on Dyne Therapeutics in a research report on Thursday, June 26th. They set a "buy" rating and a $30.00 price target on the stock. Finally, HC Wainwright lowered their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $36.25.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox bought 100,000 shares of Dyne Therapeutics stock in a transaction dated Monday, July 14th. The stock was bought at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the purchase, the chief executive officer owned 242,179 shares of the company's stock, valued at $2,206,250.69. The trade was a 70.33% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 20.77% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DYN. AQR Capital Management LLC bought a new stake in Dyne Therapeutics in the 1st quarter valued at $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock valued at $597,000 after purchasing an additional 2,886 shares during the period. Goldman Sachs Group Inc. boosted its stake in Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock valued at $10,407,000 after purchasing an additional 366,183 shares during the period. Finally, Caxton Associates LLP bought a new stake in Dyne Therapeutics in the 1st quarter valued at $157,000. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.